Analysis of Centruroides (Scorpion) Immune F(ab’)2 (Equine) administration by slow intravenous push

Abstract

Scorpion envenomation is a common emergency department presentation in Arizona and antivenom is often administered . This study evaluates the safety of Centruroides (Scorpion) Immune F(ab’)2 (Equine) administered as a single-vial-serial dosing strategy via slow intravenous push (IVP) over five minutes in the emergency department. This was a retrospective chart review of patients who received at least one vial of antivenom between April 1, 2019, and July 31, 2021. The primary outcome of this study was the rate of the serious antivenom administration-related adverse events. Twenty-five patients were included. One patient met criteria for a serious administration-related adverse event. No other serious administration, non-serious administration, or non-administration related adverse events were found. Neither grade of envenomation, repeat doses, nor total number of vials affected the rate of serious, non-serious, or non-administration-related adverse events. The primary outcome of a serious administration-related adverse event occurred in one patient (4%) with a grade IV envenomation.